Abivax S.A. (AAVXF) — SEC Filings
Abivax S.A. (AAVXF) — 29 SEC filings. Latest: 6-K (Dec 15, 2025). Includes 24 6-K, 2 20-F, 2 SC 13G/A.
Overview
Abivax S.A. (AAVXF) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 6-K filed on Sep 8, 2025: Abivax S.A. filed a 6-K report for the period ending June 30, 2025. The filing includes financial data for the first half of 2025 and the full year 2024, detailing aspects like issued capital, share premium, and retained earnings. Specific financial figures for these categories are presented for the
Sentiment Summary
Across 29 filings, the sentiment breakdown is: 3 bullish, 26 neutral. The dominant filing sentiment for Abivax S.A. is neutral.
Filing Type Overview
Abivax S.A. (AAVXF) has filed 24 6-K, 2 20-F, 2 SC 13G/A, 1 SC 13G with the SEC between Jan 2024 to Dec 2025.
Filings by Year
Recent SEC Filings (29)
Risk Profile
Risk Assessment: Of AAVXF's 22 recent filings, 0 were flagged as high-risk, 6 as medium-risk, and 16 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Key Executives
- Dominik Höchli, MD
- Dr. Philippe Pouletty
Industry Context
Abivax S.A. operates within the pharmaceutical preparations industry, focusing on the development and commercialization of innovative drugs.
Top Tags
foreign-private-issuer (8) · regulatory-filing (7) · sec-filing (6) · reporting (4) · ulcerative-colitis (3) · corporate-governance (3) · pharmaceuticals (3) · financial-update (2) · clinical-trial-results (2) · shareholder-meeting (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Reporting Period | 2025 Q2 | Indicates the financial data covers the second quarter of 2025. |
| Fiscal Year End | 12/31 | Specifies the company's fiscal year concludes on December 31st. |
| Shares with Voting Rights | 63,436,477 | Indicates the total voting power available at the shareholder meeting. |
| Total Votes Cast | 71,137,858 | Represents the aggregate votes submitted by shareholders on agenda items. |
| Shareholders Participating | 84 | Shows the number of shareholders who actively participated in the meeting's voting process. |
| Comparative Date | 2024-03-31 | Financial data includes comparative figures from March 31, 2024. |
| Year-End Date | 2023-12-31 | Financial data includes comparative figures from year-end 2023. |
| Filing Date | 2025-03-24 | The date Abivax submitted its 20-F to the SEC. |
| Clinical Trial Phase | Phase 2b | Results published in The Lancet are from this stage of testing. |
| SEC File Number | 001-41842 | Identifies Abivax's registration with the SEC. |
| Total Voting Shares | 61,012,501 | Represents the total number of shares eligible to vote. |
| Participating Shares | 49,815,120 | Indicates the number of shares that were present, represented, or voted at the meeting. |
| SIC Code | 2834 | Industry classification for Abivax S.A. |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Abivax S.A. (AAVXF)?
Abivax S.A. has 29 recent SEC filings from Jan 2024 to Dec 2025, including 24 6-K, 2 20-F, 2 SC 13G/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of AAVXF filings?
Across 29 filings, the sentiment breakdown is: 3 bullish, 26 neutral. The dominant sentiment is neutral.
Where can I find Abivax S.A. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Abivax S.A. (AAVXF) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Abivax S.A.?
Financial highlights for Abivax S.A. are available when 10-K or 10-Q filings are enriched with AI analysis. Check back as new filings are processed.
What is the investment thesis for AAVXF?
The investment thesis for AAVXF includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Abivax S.A.?
Key executives identified across Abivax S.A.'s filings include Dominik Höchli, MD, Dr. Philippe Pouletty.
What are the main risk factors for Abivax S.A. stock?
Of AAVXF's 22 assessed filings, 0 were flagged high-risk, 6 medium-risk, and 16 low-risk.
What are recent predictions and forward guidance from Abivax S.A.?
Forward guidance and predictions for Abivax S.A. are extracted from SEC filings as they are enriched.